Vraylar is considered an antipsychotic

Cariprazine more effective than risperidone

The modified intention-to-treat population included 227 (99%) of 230 patients from the cariprazine group and 229 (99%) of 230 volunteers from the risperidone arm. 178 (77%) of the patients from both study groups completed the 26-week therapy period. The mean daily doses for cariprazine were 4.2 ± 0.6 mg and for risperidone 3.8 ± 0.4 mg, the mean duration of treatment for both drugs was 182 days.

The use of cariprazine went with a greater change in the least squares mean on the PANSS-FSNS scale than that of risperidone (-8.90 points for cariprazine versus -7.44 points for risperidone; least-squares-mean-Difference -1.46; 95% confidence interval [CI] -2.39 to -0.53; p = 0.0022; Effect size 0.31).

Also with regard to the secondary endpoint, the changes in the least squares mean on the total PSP scale from baseline to endpoint, cariprazine was more effective than risperidone (14.30 points for cariprazine versus 9.66 for risperidone; 95% CI 2.71–6.56; p <0 .0001; effect size 0.48).

The therapy-related side effects were similar for both study arms. The most common were insomnia, akathisia, schizophrenia worsening, headache, and anxiety. 123 (54%) patients on cariprazine and 131 (57%) on risperidone were affected. One death in the risperidone group was unrelated to the study medication.